Long-term clinical outcomes of synchronized therapy with plasmapheresis and intravenous cyclophosphamide pulse therapy in the treatment of steroid-resistant lupus nephritis

Therapeutic Apheresis and Dialysis

Volumn 12, Issue 4, 2008, Pages 298-305

  Yamaji, Ken ^a   Kim, Young Joon ^a   Tsuda, Hiroshi ^b   Takasaki, Yoshinari ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO TOKYO KOTO GERIATRIC MEDICAL CENTER   (Japan)

Author keywords

Intravenous cyclophosphamide; Long term clinical outcome; Lupus nephritis; Plasmapheresis; Synchronized therapy

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; DNA ANTIBODY; STEROID;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG PULSE THERAPY; FEMALE; HAIR LOSS; HEMORRHAGIC CYSTITIS; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; REMISSION; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PLASMAPHERESIS; PULSE THERAPY, DRUG; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 49249125962     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2008.00591.x     Document Type: Article

References (22)

1. Flanc RS, Rober MMA, Strippoli GM. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled studies. Am J Kid Dis 2004 43: 197 208.
2. Illei GG, Takada K, Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy. Long-term follow of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002 46: 995 1002.
3. Adu D. The evidence base for the treatment of lupus nephritis in the new millennium. Nephrol Dial Transplant 2001 16: 1536 8.
4. Sugimoto K, Yamaji K, Yan KS, Kanai Y, Tsuda H, Hashimoto H. Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis. Ther Apher Dial 2006 10: 187 92.
5. Yokoyama H, Wada T, Furuichi K. Immunomodulation effects and clinical evidence of apheresis in renal diseases. Ther Apher Dial 2003 7: 513 19.
6. Clark WF, Dau PC, Euler HH et al. Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: design of the LPSG trial. Lupus Plasmapheresis Study Group (LPSG). J Clin Apher 1991 6: 40 7.
7. Euler HH, Schroeder JO, Harten P, Zeuner RA, Gutschmidt HJ. Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum 1994 37: 1784 94.
8. Wallace DJ, Goldfinger D, Pepkowitz SH et al. Randomized controlled trial of pulse / synchronization cyclophosphamide / apheresis for proliferative lupus nephritis. J Clin Apher 1998 13: 163 6.
9. Hashimoto H, Sugawara M, Tsuda H, Kabasawa K, Hirose S. Studies on the outcome of lupus nephritis according to long-term treatment employing different modes of immunotherapy. Nippon Jinzo Gakkai Shi 1992 34: 1003 9.
10. Austin HA, Klippel J, Balow JE et al. "Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs". N Engl J Med 1986 314: 614 29.
11. Boumpas DT, Austin HA Vaughn EM. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lupus 1992 340: 741 5.
12. Gourly MF, Austin HA, Scot D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996 125: 549 57.
13. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001 135: 248 57.
14. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000 35: 904 14.
15. Mok CC, Ying K, Ng WL et al. "Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide". Am J Med 2006 119: 355.e25 33.
16. Cortes-Hernandez J, Ordi-Ros J, Labrador M et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003 12: 287 96.
17. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004 350: 971 80.
18. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992 326: 1373 9.
19. Danieli MG, Palmieri C, Salvi A, Refe MC, Strusi AS, Danieli G. Synchronized therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apher 2002 17: 72 7.
20. Mistry-Burchardi N, Schonermarck U. Apheresis in lupus nephritis. Ther Apher 2001 5: 161 70.
21. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982 25: 1271 7.
22. Churg J, Sobin LH. Renal disease: Classification and atlas of glomerular disease. Tokyo, Japan, Igaku-Shoin, 1982, pp. 127 31.